Literature DB >> 3681561

Pharmacokinetics of inhaled salbutamol in patients with cystic fibrosis versus healthy young adults.

N Vaisman1, G Koren, D Goldstein, G J Canny, Y K Tan, S Soldin, P Pencharz.   

Abstract

We studied the disposition of inhaled salbutamol in adolescents with cystic fibrosis (CF) and compared it with the pharmacokinetics of the drug given by the intravenous and inhaled routes in healthy adults. After inhalation of salbutamol, CF patients had a significantly larger area under the concentration-time curve derived from amounts of drug in the systemic circulation. The differences in serum concentration of salbutamol were not reflected in differences in change of heart rate. We conclude that the rate and extent of pulmonary absorption of inhaled salbutamol in patients with CF differ from those in healthy adults.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3681561     DOI: 10.1016/s0022-3476(87)80218-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  7 in total

1.  Influence of short- and long-term inhalation of salbutamol on lung function and beta 2-adrenoceptors of mononuclear blood cells in asthmatic children.

Authors:  A Schuster; R Kozlik; D Reinhardt
Journal:  Eur J Pediatr       Date:  1991-01       Impact factor: 3.183

Review 2.  Clinical pharmacokinetics of salmeterol.

Authors:  Mario Cazzola; Renato Testi; Maria Gabriella Matera
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Treatment with rhDNase in patients with cystic fibrosis alters in-vitro CHIT-1 activity of isolated leucocytes.

Authors:  M Weckmann; C Schultheiss; A Hollaender; I Bobis; J Rupp; M V Kopp
Journal:  Clin Exp Immunol       Date:  2016-07-28       Impact factor: 4.330

Review 4.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 5.  Pharmacokinetic optimisation of asthma treatment.

Authors:  A M Taburet; B Schmit
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

7.  Impaired cardiac and peripheral hemodynamic responses to inhaled β₂-agonist in cystic fibrosis.

Authors:  Erik H Van Iterson; Stephen R Karpen; Sarah E Baker; Courtney M Wheatley; Wayne J Morgan; Eric M Snyder
Journal:  Respir Res       Date:  2015-09-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.